

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD38-Biotin, human

RRID:AB_871667

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-092-288, RRID:AB_871667

Antibody Information

URL: http://antibodyregistry.org/AB_871667

Proper Citation: Miltenyi Biotec Cat# 130-092-288, RRID:AB_871667

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-425. (RRID:AB_2733521).

Antibody Name: CD38-Biotin, human

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: IB6

Antibody ID: AB_871667

Vendor: Miltenyi Biotec

Catalog Number: 130-092-288

Record Creation Time: 20250820T070657+0000

Record Last Update: 20250821T013756+0000

Ratings and Alerts

No rating or validation information has been found for CD38-Biotin, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-425. (RRID:AB_2733521).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Heider M, et al. (2021) The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Molecular cell, 81(6), 1170.